Heart failure is a common and serious comorbidity in diabetes, requiring targeted treatment with glycemic control, ACE inhibitors, and beta-blockers to prevent myocardial remodeling.
Highlights HF screening in diabetes; leaves open optimal integration of newer agents with standard therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
David S.H. Bell (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: